Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Clinical characteristics of patients with chronic hepatitis B (CHB) who developed genotypic resistance to entecavir (ETV) were compared to those without resistance. Methods: Two hundred fifty eight CHB patients who underwent ETV treatment in our institution from July 2007 to May 2013 were included. Results: Eight (3.1%) patients developed genotypic resistance to ETV during the follow-up period. The patterns of genotypic resistance to ETV were as follows: L180M + M204V + S202G (n=3); M204I + V173M (n=1); I169V + V173M (n=1); L180M + M204V + V173L (n=1); L180M + M204V + V173L + M250V (n=1); M204I + V214A + P237H (n=1). The cumulative occurrence rates of genotypic resistance to ETV were not significantly different between CHB patients with prior nucleos(t)tide analogues (NA) exposure (NA experienced, n=56) and NA naïve patients (n=202, P=0.823 by log rank comparison). Older age, higher baseline log10hepatitis B virus-deoxynucleic acid (log10HBV-DNA), higher log10HBV-DNA at 3, 6, 12 and 24 months after baseline, and complete virologic response (CVR, undetectable serum HBV-DNA by polymerase chain reaction 6 months after ETV treatment) were significant contributors to the development of genotypic resistance to ETV. Multivariate analyses showed higher log10HBV-DNA 6 months after baseline and absence of CVR were independent and significant contributors to the development of ETV resistance. Conclusions: Clinical characteristics of patients who developed ETV resistance were higher log10HBV-DNA 6 months after baseline and absence of CVR during the ETV treatment.
Abstract
Background/Aims: Clinical characteristics of patients with chronic hepatitis B (CHB) who developed genotypic resistance to entecavir (ETV) were compared to those without resistance. Methods: Two hundred fifty eight CHB patients who underwent ETV treatment in our institution from July 2007 to May 2013 were included. Results: Eight (3.1%) patients developed genotypic resistance to ETV during the follow-up period. The patterns of genotypic resistance to ETV were as follows: L180M + M204V + S202G (n=3); M204I + V173M (n=1); I169V + V173M (n=1); L180M + M204V + V173L (n=1); L180M + M204V + V173L + M250V (n=1); M204I + V214A + P237H (n=1). The cumulative occurrence rates of genotypic resistance to ETV were not significantly different between CHB patients with prior nucleos(t)tide analogues (NA) exposure (NA experienced, n=56) and NA naïve patients (n=202, P=0.823 by log rank comparison). Older age, higher baseline log10hepatitis B virus-deoxynucleic acid (log10HBV-DNA), higher log10HBV-DNA at 3, 6, 12 and 24 months after baseline, and complete virologic response (CVR, undetectable serum HBV-DNA by polymerase chain reaction 6 months after ETV treatment) were significant contributors to the development of genotypic resistance to ETV. Multivariate analyses showed higher log10HBV-DNA 6 months after baseline and absence of CVR were independent and significant contributors to the development of ETV resistance. Conclusions: Clinical characteristics of patients who developed ETV resistance were higher log10HBV-DNA 6 months after baseline and absence of CVR during the ETV treatment.
참고문헌 (18)
- Yuen MF, "Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications", Gut, 54, pp.1610~1614 (2005)
- Keeffe EB, "A treatment algorithm for the management of chronic hepatitis B virus infection in the United States", Clin Gastroenterol Hepatol, 2, pp.87~106 (2004)
- Hoofnagle JH, "Management of hepatitis B: summary of a clinical research workshop", Hepatology, 45, pp.1056~1075 (2007)
- Lok AS, "Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management", Hepatology, 46, pp.254~265 (2007)
- Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
- European Association For The Study Of The Liver, "EASL Clinical Practice Guidelines: management of chronic hepatitis B", J Hepatol, 50, pp.227~242 (2009)
- Langley DR, "Inhibition of hepatitis B virus polymerase by entecavir", J Virol, 81, pp.3992~4001 (2007)
- Seifer M, "In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475and lobucavir", Antimicrob Agents Chemother, 42, pp.3200~3208 (1998)
- Colonno RJ, "Entecavir resistance is rare in nucleoside naïve patients with hepatitis B", Hepatology, 44, pp.1656~1665 (2006)
- Tenney DJ, "Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine", Antimicrob Agents Chemother, 48, pp.3498~3507 (2004)
- Tenney DJ, "Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naïve patients", J Hepatol, 50, pp.S10~ (2009)
- Tenney DJ, "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy", Hepatology, 49, pp.1503~1514 (2009)
- Yuen MF, "Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety", Am J Gastroenterol, 106, pp.1264~1271 (2011)
- Manns MP, "Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901", Expert Opin Drug Saf, 11, pp.361~368 (2012)
- Zoutendijk R, "Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response", Hepatology, 54, pp.443~451 (2011)
- Bang SJ, "Clinical course of patients with insufficient viral suppression during entecavir therapy in genotype C chronic hepatitis B", Dig Liver Dis, 45, pp.600~605 (2013)
- Lee JH, "Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance", Antimicrob Agents Chemother, 58, pp.1730~1737 (2014)
- Wong GL, "Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years", Aliment Pharmacol Ther, 35, pp.1326~1335 (2012)